- Home
- TPST vs SCYX Comparison
TPST vs SCYX Comparison
Compare TPST & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- SCYX
- Stock Information
- Founded
- TPST 2011
- SCYX 1999
- Country
- TPST United States
- SCYX United States
- Employees
- TPST N/A
- SCYX N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- SCYX Health Care
- Exchange
- TPST Nasdaq
- SCYX Nasdaq
- Market Cap
- TPST 33.0M
- SCYX 28.5M
- IPO Year
- TPST N/A
- SCYX 2014
- Fundamental
- Price
- TPST $6.86
- SCYX $0.67
- Analyst Decision
- TPST Hold
- SCYX
- Analyst Count
- TPST 3
- SCYX 0
- Target Price
- TPST $30.00
- SCYX N/A
- AVG Volume (30 Days)
- TPST 247.2K
- SCYX 109.2K
- Earning Date
- TPST 08-07-2025
- SCYX 08-07-2025
- Dividend Yield
- TPST N/A
- SCYX N/A
- EPS Growth
- TPST N/A
- SCYX N/A
- EPS
- TPST N/A
- SCYX N/A
- Revenue
- TPST N/A
- SCYX $2,630,000.00
- Revenue This Year
- TPST N/A
- SCYX $463.61
- Revenue Next Year
- TPST N/A
- SCYX $310.80
- P/E Ratio
- TPST N/A
- SCYX N/A
- Revenue Growth
- TPST N/A
- SCYX N/A
- 52 Week Low
- TPST $5.35
- SCYX $0.67
- 52 Week High
- TPST $30.03
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- TPST 49.91
- SCYX 37.94
- Support Level
- TPST $6.87
- SCYX $0.72
- Resistance Level
- TPST $7.25
- SCYX $0.85
- Average True Range (ATR)
- TPST 0.67
- SCYX 0.05
- MACD
- TPST -0.02
- SCYX -0.01
- Stochastic Oscillator
- TPST 11.20
- SCYX 9.61
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.